cannabidiol (CBD) was found to b effective in reducing total area covered by artherosclerotic plaques (composed of the number and/or size of atherosclerotic plaques) in aortas and in lowering triglycerides, LDL and cholesterol levels in in-vivo...

cannabidiol (CBD) was found to b effective in reducing total area covered by artherosclerotic plaques (composed of the number and/or size of atherosclerotic plaques) in aortas and in lowering triglycerides, LDL and cholesterol levels in in-vivo models. In addition in vivo administration of CBD was found to reduce the infarct scar size in rat hearts after surgically induced infarct. keywords: atherosclerosis, lowering cholesterol

Reduces atherosclerotic plaque, lowers cholesterol

Categories	Cardiovascular, Inflammation
Development Stage	All experiments to date conducted on knock-out mice
Patent Status	U.S. patent filed
Market Size	The cholesterol drug market is a $20 billion a year industry

Highlights

• Cannabidiol, a non-psychoactive cannabis constituent reduces number and size of atherosclerotic plaque, lower triglycerides, LDL and cholesterol levels and decreases scar size after myocardial infract (MI)
• Successful results demonstrated in knock-out mice (APO-E-).
• Alternative therapy to current cholesterol reducing drugs and may be a medicament for administration after MI to diminish future damage  
• Administration in mice: IP, SC injections, oral and patch

Our Innovation

• Cannabidiol compound for the treatment of atherosclerosis. New approach for reducing plaques and lowering cholesterol and for minimizing scar size after MI .

Key Features

• No side effects
• No psychotropic effects
• Relatively low-cost treatment

Development Milestones

• Ongoing trials for another diseases
• Development of oral and patch delivery

The Opportunity

• Approx 1 in 58 (1.7%) or 4.6 million people in USA suffer from atherosclerosis
• Promising new anti-atherosclerosis drugs are projected to match the success of the current multibillion-dollar lipid-lowering drugs market
• Other emerging products, such as high-density lipoprotein-boosting anti-atherosclerosis biotherapies, will reach the U.S. market during the next five years

project-id 12-2006-616

U.S. patent filed.